ANGIOTENSIN II RECEPTOR ANTAGONISTS

摘要

The compounds of the present invention are polymorphic crystalline forms of the compound 2-butyl-4-chloro-1-[(2~-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl ]- imidazole-5-carboxylic acid, which has the structure (I). Specifically, the compounds of the invention are selected from the group consisting of 2-butyl -4- chloro-1-[(2~-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxyli c acid of Claim 3 selected from the group consisting of 2-butyl-4-chloro-1-[(2 ~- (1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form I, 2-butyl-4-chloro-1-[(2~-(1-H-tetrazol-5-yl)biphenyl-4- yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form II, 2-butyl-4-chlo ro- 1-[(2~-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form III, and 2-butyl-4-chloro-1-[(2~-(1-H-tetrazol-5- yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form IV, 2- butyl-4-chloro-1-[(2~-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5- carboxylic acid monohydrate Form V, 2-butyl-4-chloro-1-[(2~-(1-H-tetrazol-5- yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VI, 2- butyl-4-chloro-1-[(2~-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5- carboxylic acid monohydrate Form VII, and 2-butyl-4-chloro-1-[(2~-(1-H- tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VIII.